Looking for 10x surge stock, Here it is
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious and life-threatening diseases, with a focus on rare genetic disorders.
This company stock has been under performing for past 5 years with decline rate of 99% from its price 5 years ago. The price is range bound for past 4+ years $3 to $5. Major reasons I correlate for the indeed decline are
* Allocation of less operational budgets since 2018
* COVID influences on Market
* Early-stage biotechs focused on rare disease therapies
Why I consider there will be a surge of 10x price hikes
1. After long struggle in the rare disease therapies research , this company succeeded for first time in launching
ZEVASKYN® (prademagene zamikeracel, formerly pz-cel): An FDA-approved autologous, cell-based gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare skin disorder.
On December 8, 2025, the company reported the first patient treated with ZEVASKYN gene therapy. 
2. Several programs in preclinical trials and 6 major programs are in close partnership with other reputed & successful organizations (High chances of FDA approval in clinical trials.
3. Strong Technicals : Price surge testing 50 & 200 of weekly Moving Average and sustained above 50 weekly MA; with 20x surge in volume (2M avg weekly volume to 40M volume).
4. 50 Weekly MA crossover with 200 WMA and about to break out 200 WMA.
5. No known legal/law suits or issues with the company. Higher respect and growth prospects.
Overall I am strongly bullish on this. 200 WMA breakout will give a surge of price anywhere from 5x to 10x returns in very short term. 25X to 40X returns in long term.
Note: Please do your own study and invest with caution.
